Potential mechanism of enhanced postprandial glucagon-like peptide-1 release following treatment with a diacylglycerol acyltransferase 1 inhibitor

Pharmacology Research and Perspectives

Volumn 3, Issue 6, 2015, Pages 1-10

  Liu, Jinqi ^a   Mclaren, David G ^a   Chen, Dunlu ^a   Kan, Yanqing ^a   Stout, Steven J ^a   Shen, Xiaolan ^a   Murphy, Beth Ann ^a   Forrest, Gail ^a   Karanam, Bindhu ^a   Sonatore, Lisa ^a   He, Shuwen ^a   Roddy, Thomas P ^b   Pinto, Shirly ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b AGIOS PHARMACEUTICALS   (United States)

Author keywords

DGAT1 inhibitor; GLP 1 release; Intestine; Lipid partition

Indexed keywords

ACYLTRANSFERASE INHIBITOR; CHOLESTEROL ESTER; DIACYLGLYCEROL ACYLTRANSFERASE 1; DIACYLGLYCEROL ACYLTRANSFERASE 1 INHIBITOR; GLUCAGON LIKE PEPTIDE 1; LIPID; PHOSPHATIDYLCHOLINE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ENTEROENDOCRINE CELL; ENZYME ASSAY; FAT INTAKE; FECES ANALYSIS; HORMONE RELEASE; HUMAN; HUMAN CELL; IC50; IMMUNOASSAY; LIPID ANALYSIS; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MOUSE; NONHUMAN; POSTPRANDIAL STATE; PRIORITY JOURNAL; STOMACH EMPTYING;

EID: 85014129989     PISSN: None     EISSN: 20521707     Source Type: Journal    
DOI: 10.1002/prp2.193     Document Type: Article

References (29)

1. Ables GP, Yang KJ, Vogel S, Hernandez-Ono A, Yu S, Yuen JJ, et al. (2012). Intestinal DGAT1 deficiency markedly reduces postprandial triglyceride and retinyl ester excursions by inhibiting chylomicron secretion and delaying gastric emptying. J Lipid Res 53: 2364-2379.
2. Brubaker PL (2006). The glucogan-like peptides: pleiotropic regulators of nutrient homeostasis. Ann N Y Acad Sci 1070: 10-26.
3. Buhman KK, Sj Smith, Stone SJ, Repa JJ, Wong JS, Knapp FF Jr, et al. (2002). DGAT1 is not essential for intestinal triacylglycerol absorption or chylomicron synthesis. J Biol Chem 277: 25474-25479.
4. Cao J, Zhou Y, Peng H, Huang X, Stahler S, Suri V, et al. (2011). Targeting acyl-CoA:diacylglycerol acyltransferase 1 (DGAT1) with small molecule inhibitors for the treatment of metabolic diseases. J Biol Chem 286: 41838-41851.
5. Capeau J (2008). Insulin resistance and steatosis in humans. Diabetes Metab 34: 649-657.
6. Chu ZL, Carroll C, Alfonso J, Gutierrez V, He H, Lucman A, et al. (2008). A role for intestinal endocrine cell-expressed G protein-coupled receptor 119 in glycemic control by enhancing glucagon-like peptide-1 and glucose-dependent insulinotropic peptide release. Endocrinology 149: 2038-2047.
7. DeVita RJ, Pinto S (2013). Current status of the research and development of diacylglycerol o-acyltransferase 1 (DGAT1) inhibitors. J Med Chem 56: 9820-9825.
8. Drucker DJ (2002). Biological actions and therapeutic potential of the glucagon like peptides. Gastroenterology 122: 531-544.
9. Edfalk S, Steneberg P, Edlubd H (2008). GPR40 is expressed in enteroendocrine cells and mediates free fatty acid stimulation of incretin secretion. Diabetes 57: 2280-2287.
10. Ellrichmann M, Kapelle M, Ritter PR, Holst JJ, Herzig KH, Schmidt WE, et al. (2008). Orlistat inhibition of intestinal lipase acutely increases appetite and attenuates postprandial glucagon-like-peptide-1(7-36)-amide-1, cholecystokinin, and peptide YY concentrations. J Clin Endocrinol Metab 93: 3995-3998.
11. Ferraris RP, Yasharpour S, Lloyd KCK, Mirzayan R, Diamond JM (1990). Luminal glucose concentrations in the gut under normal conditions. Am J Physiol Gastrointest Liver Physiol 259: G822-G837.
12. Hirasawa A, Tsumaya K, Awaji T, Katsuma S, Adachi T, Tamada M, et al. (2005). Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120. Nat Med 11: 90-94.
13. Iakoubov R, Izzo A, Yeung A, Whiteside CI, Brubaker PL (2007). Protein kinase C zeta Is required for oleic acid-induced secretion of glucagon-like peptide-1 by intestinal endocrine L cells. Endocrinology 148: 1089-1098.
14. Kaemerer E, Plum P, Klaus C, Weiskirchen R, Liedtke C, Adolf M, et al. (2010). Fatty acid binding receptors in intestinal physiology and pathophsiology. World J Gastrointest Pathophysiol 1: 147-153.
15. Lan H, Lin HV, Wang CF, Wright MJ, Xu S, Kang L, et al. (2012). Agonists at GPR119 mediate secretion of GLP-1 from mouse enteroendocrine cells through glucose-independent pathways. Br J Pharmacol 165: 2799-2807.
16. Lin HC, Zhao XT, Wang L (1996). Fat absorption is not complete by midgut but is dependent on load of fat. Am J Physiol 271: G62-G67.
17. Liu J, Gorski J, Chen D, Chen S, Forrest G, Itoh Y, et al. (2013). Pharmacological inhibition of diacylglycerol acyltransferase 1 reduces body weight and modulates gut peptide release - potential insight into mechanism of action. Obesity 21: 1406-1415.
18. Luo J, Swaminath G, Brown SP, Zhang J, Guo Q, Chen M, et al. (2012). A potent class of GPR40 full agonists engages the enteroinsular axis to promote glucose control in rodents. PLoS ONE 7: e46300.
19. Maciejewski BS, LaPerle JL, Chen D, Ghosh A, Zavadoski WJ, McDonald TS, et al. (2013). Pharmacological inhibition to examine the role of DGAT1 in dietary lipid absorption in rodents and humans. Am J Physiol Gastrointest Liver Physiol 304: G958-G969.
20. Mansbach CM, Gorelick F (2007). Development and physiological regulation of intestinal lipid absorption. II. Dietory lipid absorption, complex lipid synthesis, and the intracellular packaging and secretion of chylomicrons. Am J Physiol Gastrointest Liver Physiol 293: G645-G650.
21. Matzinger D, Degen L, Drewe J, Meuli J, Duebendorfer R, Ruckstuhl N, et al. (2000). The role of long chain fatty acids in regulating food intake and cholecystokinin release in humans. Gut 46: 688-693.
22. McLaren DG, He T, Wang S-P, Mendoza V, Rosa R, Gagen K, et al. (2011). The use of stable-isotopically labeled oleic acid to interrogate lipid assembly in vivo: assessing pharmacological effects in preclinical species. J Lipid Res 52: 1150-1161.
23. McLaren DG, Cardasis HL, Stout SJ, Wang SP, Mendoza V, Castro-Perez JM. (2013). The use of [13C18] oleic acid and mass isotopomer distribution analysis to study synthesis of plasma triglycerides in vivo: analytical and experimental considerations. Anal Chem 85: 6287-6294.
24. Okawa M, Fujii K, Ohbuchi K, Okumoto M, Aragane K, Sato H, et al. (2009). Role of MGAT2 and DGAT1 in the release of gut peptides after triglyceride ingestion. Biochem Biophys Res Commun 390: 377-381.
25. Reimer RA, Darimont C, Gremlich S, Nicolas-Métral V, Rüegg UT, Macé K (2001). A human cellular model for studying the regulation of glucagon-like peptide-1 secretion. Endocrinology 142: 4522-4528.
26. Roberge JN, Brubaker PL (1993). Regulation of intestinal proglucagon-derived peptide secretion by glucose-dependent insulinotropic peptide in a novel enteroendocrine loop. Endocrinology 133: 233-240.
27. Rocca AS, Brubaker PL (1995). Stereospecific effects of fatty acids on proglucagon-derived peptide secretion in fetal rat intestinal cultures. Endocrinology 136: 5593-5599.
28. Rocca AS, LaGreca J, Kalitsky J, Brubaker PL (2001). Monosaturated fatty acid diets improve glycemic tolerance through increased secretion of glucagon-like peptide-1. Endocrinology 142: 1148-1155.
29. Visbøll T, Krarup T, Madsbad S, Holst JJ (2003). Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects. Regul Pept 114: 115-121.